Drugs / ARC-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07691606 | Jun 2026 → Jan 2029 expected | B-cell non-Hodgkin lymphoma | Taiho Oncology, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-28 | Taiho Oncology, Inc. | Regulatory Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development taiho.co.jp ↗
the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02 |
| 2026-04-27 | Taiho Oncology, Inc. | Regulatory Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development taihooncology.com ↗
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-23 | Taiho Oncology, Inc. | Araris Biotech AG and Taiho Oncology Announce Dosing of First Patient in Phase 1 Trial of ARC-02, a Novel ADC for the Treatment of Non-Hodgkin Lymphoma taihooncology.com ↗ |
| 2026-04-28 | Taiho Oncology, Inc. | Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development taiho.co.jp ↗ |
| 2026-04-27 | Taiho Oncology, Inc. | Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development taihooncology.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARC-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07691606 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion.” NCT07691606 ↗ |